4/16/99

NIHON KOHDEN AMERICA, INC. January 4, 1999 K996031

510(k) NOTIFICATION ECG-9010K and ECG-9020K Cardiofax GEM

SECTION 2 - 510(K) SUMMARY

Name and Address of Applicant Nihon Kohden America, Inc. Attn: Regulatory Affairs 2601 Campus Drive Irvine, California 92612-1601 (949) 250-3959

The ECG-9010K and ECG-9020K have been classified as Class III by the Division of Cardiovascular, Respiratory, and Neurological Devices and the Cardiovascular Device Classification Panel under 21 CFR Part 870.2340 "Electrocardiograph" as per 74 LOS.

Common names for the ECG-9010K and ECG-9020K include ECG and electrocardiograph.

Nihon Kohden's model ECG-9010K and ECG-9020K are intended for medical purposes to process the electrical signals transmitted through two or more electrocardiograph electrodes and to produce a visual display and/or prepare a record of the electrical signals produced by the heart.

The ECG-9010K and ECG-9020K devices comply with the IEC 601-1 standard including subclause 56.3(c) implemented by 21 CFR Part 868 Performance Standard for Electrode Lead Wires and Patient Cables. To date, no other special controls or performance standards are known or established for these devices. The devices are also in compliance with the following voluntary industrial standards: IEC 601-2-25 and CSA 601-1. Defibrillator Discharge Protection: Class I, Type CF.

The ECG-9010K and ECG-9020K are not intended to be sterile.

The devices were determined to be non-contacting. Therefore, good laboratory practice studies were not required per 21 CFR part 58.

The ECG-9010K and ECG-9020K were subjected to electromagnetic, environmental, safety and performance testing procedures. These tests verified the operation of the device. Software validation is performed to test the operation of the device software. The results confirm that the device performs within specifications.

Therefore based on the above, Nihon Kohden believes that the ECG-9010K and ECG-9020K are substantially equivalent to the ECG-9320A.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

APR 1 6 1999

Mr. Gary Reasoner Nihon Kohden America, Inc. 2601 Campus Drive Irvine, CA 92612

Re: K990031

Nihon Kohden ECG-9010K and ECG-9020K Cardiofax Gem

and Accessories

Regulatory Class: III (three)

Product Code: 74 LOS Dated: April 6, 1999 Received: April 7, 1999

Dear Mr. Reasoner:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Thomas J. Callahan, Ph.D.

Director

Division of Cardiovascular,
Respiratory, and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

NIHON KOHDEN AMERICA, INC. January 4, 1999

510(k) NOTIFICATION ECG-9010K and ECG-9020K Cardiofax GEM

G. Indications for Use Statemen	t	
510(k) Number (if known):	K990031	
Device Name: ECG-9010K and EC	CG-9020K Cardiofax GEM	
Indications for Use:		-
purposes to process the ele	ectrical signals transmitted	ectrocardiographs are intended for medical I through two or more electrocardiograph are a record of the electrical signals produced by
For non-interpretive application range of patient population ECG program intended for	is as determined by a clinic	d ECG-9020K are intended for use with a full cian. The devices also provide an interpretive ears to adult.
morphology to assist the pl are not intended as the sol	hysician in diagnosis. Ass e basis for diagnosis. All a	assessment of ECG waveform rhythm and essments provided by the interpretation program assessments provided by the interpretation sysicians trained in electrocardiography.
(Divi Divis and N	THIS LINE - CONTINUE OF THIS LINE - CONTINUE OF THE PROPERTY O	Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)	OR	Over-The-Counter Use

(Optional Format 1-2-96)